120 related articles for article (PubMed ID: 36965981)
21. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
[TBL] [Abstract][Full Text] [Related]
22. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
23. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
25. HPV-negative high-grade cervical precancerous lesions or invasive cancer in China: A post hoc analysis of a multicentric clinical study.
Bao H; Zhao Y; Zhang X; Bi H; Cong S; Fang L; Wang HJ; Wang L
Int J Gynaecol Obstet; 2023 Apr; 161(1):159-167. PubMed ID: 36444986
[TBL] [Abstract][Full Text] [Related]
26. Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.
Boers A; Wang R; van Leeuwen RW; Klip HG; de Bock GH; Hollema H; van Criekinge W; de Meyer T; Denil S; van der Zee AGJ; Schuuring E; Wisman GBA
Clin Epigenetics; 2016; 8():29. PubMed ID: 26962367
[TBL] [Abstract][Full Text] [Related]
27. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
28. Risk of high-risk human papillomavirus infection and cervical precancerous lesions with past or current trichomonas infection: a pooled analysis of 25,054 women in rural China.
Feng RM; Z Wang M; Smith JS; Dong L; Chen F; Pan QJ; Zhang X; Qiao YL; Zhao FH
J Clin Virol; 2018; 99-100():84-90. PubMed ID: 29396352
[TBL] [Abstract][Full Text] [Related]
29. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
30. Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trial.
Broberg G; Jonasson JM; Ellis J; Gyrd-Hansen D; Anjemark B; Glantz A; Söderberg L; Ryd ML; Holtenman M; Milsom I; Strander B
Int J Cancer; 2013 Jul; 133(1):164-71. PubMed ID: 23233356
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of screening performance between primary high-risk HPV screening and high-risk HPV screening plus liquid-based cytology cotesting in diagnosis of cervical precancerous or cancerous lesions].
Zhao XL; Remila R; Hu SY; Zhang L; Xu XQ; Chen F; Pan QJ; Zhang X; Zhao FH
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 May; 52(5):469-474. PubMed ID: 29747337
[No Abstract] [Full Text] [Related]
33. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
[TBL] [Abstract][Full Text] [Related]
34. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3.
Xi LF; Koutsky LA; Castle PE; Wheeler CM; Galloway DA; Mao C; Ho J; Kiviat NB
J Natl Cancer Inst; 2009 Feb; 101(3):153-61. PubMed ID: 19176451
[TBL] [Abstract][Full Text] [Related]
36. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
37. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
38. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
39. Risk of invasive cervical cancer in relation to clinical investigation and treatment after abnormal cytology: a population-based case-control study.
Silfverdal L; Kemetli L; Sparén P; Andrae B; Strander B; Ryd W; Dillner J; Törnberg S
Int J Cancer; 2011 Sep; 129(6):1450-8. PubMed ID: 21064110
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for cervical precancer detection among previously unscreened HIV-infected women in Western Kenya.
Huchko MJ; Leslie H; Sneden J; Maloba M; Abdulrahim N; Bukusi EA; Cohen CR
Int J Cancer; 2014 Feb; 134(3):740-5. PubMed ID: 23900762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
